NCT07166406 - Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

October 2, 2025

Primary Completion Date

March 10, 2029

Study Completion Date

March 10, 2029

Conditions

Advanced Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8

Interventions

BIOLOGICAL

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT and PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Tremelimumab

Given IV

BIOLOGICAL

Durvalumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Ipilimumab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo liver SBRT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT